These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 9863885)

  • 21. DMP 266 and indinavir combination.
    AIDS Patient Care STDS; 1997 Aug; 11(4):287-8. PubMed ID: 11361845
    [No Abstract]   [Full Text] [Related]  

  • 22. Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication.
    Ioannidis JP; Havlir DV; Tebas P; Hirsch MS; Collier AC; Richman DD
    AIDS; 2000 Jul; 14(11):1481-8. PubMed ID: 10983634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy.
    Weverling GJ; Lange JM; Jurriaans S; Prins JM; Lukashov VV; Notermans DW; Roos M; Schuitemaker H; Hoetelmans RM; Danner SA; Goudsmit J; de Wolf F
    AIDS; 1998 Jul; 12(11):F117-22. PubMed ID: 9708401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiviral update.
    PI Perspect; 1996 Nov; (No 20):8-9. PubMed ID: 11363972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized trial comparing the introduction of ritonavir or indinavir in 1251 nucleoside-experienced patients with advanced HIV infection.
    Floridia M; Tomino C; Bucciardini R; Ricciardulli D; Fragola V; Pirillo MF; Amici R; Giannini G; Galluzzo CM; Andreotti M; Seeber AC; Ammassari A; Cingolani A; Lazzarin A; Scalise G; Cargnel A; Suter F; Milazzo F; Pastore G; Moroni M; Ciammarughi R; Pini R; Carosi G; D'Amato C; Contu L; Concia E; Bonazzi L; Aiuti F; Vigevani G; Vella S;
    AIDS Res Hum Retroviruses; 2000 Nov; 16(17):1809-20. PubMed ID: 11118067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ritonavir boosted indinavir treatment as a simplified maintenance "mono"-therapy for HIV infection.
    Kahlert C; Hupfer M; Wagels T; Bueche D; Fierz W; Walker UA; Vernazza PL
    AIDS; 2004 Apr; 18(6):955-7. PubMed ID: 15060447
    [No Abstract]   [Full Text] [Related]  

  • 27. Early intensification with abacavir in subjects at high risk for incomplete viral suppression.
    Bartlett JA; Tebas P; Bassett R; Huang W; Kuritzkes D; Reisler R; Loyack N; Robison K;
    Antivir Ther; 2003 Aug; 8(4):361-3. PubMed ID: 14518706
    [No Abstract]   [Full Text] [Related]  

  • 28. Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients.
    Ibáñez A; Puig T; Elias J; Clotet B; Ruiz L; Martínez MA
    AIDS; 1999 Jun; 13(9):1045-9. PubMed ID: 10397534
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of 2-year antiretroviral combination therapies on HIV-1 DNA levels.
    Zanussi S; Bortolin MT; Tirelli U; Nasti G; Vaccher E; Giacca M; De Paoli P
    J Acquir Immune Defic Syndr; 2000 Apr; 23(5):439-41. PubMed ID: 10866240
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma.
    Lebbé C; Blum L; Pellet C; Blanchard G; Vérola O; Morel P; Danne O; Calvo F
    AIDS; 1998 May; 12(7):F45-9. PubMed ID: 9619797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for ritonavir intolerance and outcome after change to indinavir.
    Casado JL; Perez-Elías MJ; Antela A; Martí-Belda P; de Lucas S; Muñoz V; Guerrero A
    AIDS; 1998 Feb; 12(3):335-6. PubMed ID: 9580044
    [No Abstract]   [Full Text] [Related]  

  • 32. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.
    García F; Plana M; Vidal C; Cruceta A; O'Brien WA; Pantaleo G; Pumarola T; Gallart T; Miró JM; Gatell JM
    AIDS; 1999 Jul; 13(11):F79-86. PubMed ID: 10449278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiretroviral therapy: where are we?
    Hammer SM; Yeni P
    AIDS; 1998; 12 Suppl A():S181-8. PubMed ID: 9633001
    [No Abstract]   [Full Text] [Related]  

  • 34. A controlled trial of double versus triple therapy for HIV.
    Feldmesser M; Falkenberg J
    N Engl J Med; 1998 Jan; 338(3):196; author reply 197. PubMed ID: 9441224
    [No Abstract]   [Full Text] [Related]  

  • 35. Abacavir (1592) with protease inhibitors in potent antiretroviral activity.
    AIDS Patient Care STDS; 1998 Apr; 12(4):315-6. PubMed ID: 11361959
    [No Abstract]   [Full Text] [Related]  

  • 36. Improvement in CD4+ cell counts despite persistently detectable HIV load.
    Levitz SM
    N Engl J Med; 1998 Apr; 338(15):1074-5. PubMed ID: 9537882
    [No Abstract]   [Full Text] [Related]  

  • 37. [HIV protease inhibitors. A new drug class in antiretroviral therapy].
    Mauss S; Seidlitz B; Jablonowski H; Häussinger D
    Dtsch Med Wochenschr; 1996 Nov; 121(44):1369-74. PubMed ID: 8964223
    [No Abstract]   [Full Text] [Related]  

  • 38. Phenotypic patterns of HIV-1 clonal populations during highly active antiretroviral therapy (HAART).
    Favia A; Di Stefano M; Fiore JR; Pastore G; Angarano G
    New Microbiol; 1999 Oct; 22(4):301-7. PubMed ID: 10555199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protease inhibitor and triple-drug therapy: cellular immune parameters are not restored in pediatric AIDS patients after 6 months of treatment.
    Chougnet C; Fowke KR; Mueller BU; Smith S; Zuckerman J; Jankelevitch S; Steinberg SM; Luban N; Pizzo PA; Shearer GM
    AIDS; 1998 Dec; 12(18):2397-406. PubMed ID: 9875577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of indinavir and ritonavir on warfarin anticoagulant activity.
    Gatti G; Alessandrini A; Camera M; Di Biagio A; Bassetti M; Rizzo F
    AIDS; 1998 May; 12(7):825-6. PubMed ID: 9619821
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.